State Street Health Care Select Sector SPDR ETF

XLV

Market cap $38.5B

LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.

Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.

Tony Dong is the founder of ETF Portfolio Blueprint.

There are several different paths to retiring on dividends. However, they all have major drawbacks. I share an approach that I have honed over time that seeks to bring out the best of each strategy and minimize its deficiencies.

Sure, portfolio diversification may be important, but some equity sectors currently look a bit more promising than others. Key Takeaways: Diversification may be a valuable portfolio approach, but individual equity sectors like healthcare may warrant concentrated exposure.

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

April jobs beat forecasts as healthcare, transportation and retail hiring stayed resilient. These sector ETFs and stocks may stay active.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Healthcare is supposed to be the place you hide. It is the fourth-largest slice of U.S.

Recent White House and FDA actions fast-track psychedelic depression drug approvals, granting priority review vouchers and accelerating rescheduling for eligible therapies. Compass Pathways leads with a CNPV for COMP360 in treatment-resistant depression, positive Phase 3 data, and a sub-$1bn market cap suggesting potential upside.